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Objectives:  The  present  study  was  undertaken  to evaluate  the  anti-fungal  activity  of amphotericin  B
(AMPH-B),  ﬂucytosine  (5-FC),  ﬂuconazole  (FLCZ),  miconazole  (MCZ),  itraconazole  (ITCZ),  and  micafun-
gin  (MCFG)  against  clinically  isolated  Candida  strains  from  oral  candidiasis  (OC)  patients  and  to  collect
information  useful  for the treatment  of OC.
Subjects and  methods:  The study  includes  116  strains  of  Candida  isolated  from  patients.  The  Candida  species
were  identiﬁed  by  polymerase  chain  reaction.  The  minimum  inhibitory  concentration  (MIC)  of  each  drug
against  each  Candida  species  was  determined.
Results: Of  the  106  participants  (30  males  and  76 females),  57  had  OC,  including  42  cases  of pseu-
domembranous  OC,  11  cases  of erythematous  OC,  2 cases  of  hypertrophic  OC,  and  2  cases  of  mixed
pseudomembranous/erythematous  OC.  The  Candida  species  isolated  were  Candida  albicans  (93 strains),
C.  glabrata  (19 strains),  and  C.  tropicalis  (4 strains).  AMPH-B  and  5-FC  had  low  MIC  values  against  all
species  of  Candida  and  a low  incidence  of  resistance  development.  In  some  species  of  Candida,  FLCZ  and
ITCZ  showed  high  MICs,  but  MCZ  had  a  low  MIC  value.  AMPH-B,  MCZ,  and  ITCZ  prescribed  to  OC patients
were  effective  against  OC  with  respect  to  alleviation  of  OC symptoms.
Conclusion: MIC values  of  anti-fungal  drugs  against  Candida  strains  isolated  from  OC  patients  were
obtained  and  the  3 anti-fungal  drugs  given  to OC  patients  were  found  to be  effective  against  OC in  spite  of
differences  in  their  MIC  values  and  in  the number  of  resistant  strains  (or  strains  with  a  high  MIC  value).
 Japan© 2013
. Introduction
Since a paper published early in the 1990s reported that
andida albicans resistant to ﬂuconazole (FLCZ) was frequently
solated from the oral cavity of acquired immunity deﬁciency
yndrome patients, epidemiologic studies have been actively con-
ucted to determine the susceptibility of Candida strains isolated
rom patients with invasive candidiasis [1]. Examples of global-
cale surveillance of the resistance of genus Candida to anti-fungal
rugs include the report of the SENTRY Program on resistance to
mphotericin-B (AMPH-B) in 2006–2007 [2] and the reports of
urveillance of susceptibility to drugs of the candin family [3–6].
∗ Corresponding author. Tel.: +81 992756232.
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348-8643/$ – see front matter ©  2013 Japanese Stomatological Society. Published by Els
ttp://dx.doi.org/10.1016/S1348-8643(13)00006-2ese Stomatological Society. Published by Elsevier Ltd. All rights reserved.
In Japan, reports have been made concerning Surveillance 99 by
the Japan Invasive Mycosis Surveillance study group (JIMS) [7] and
the Program on the Japan Antifungal Surveillance (JAS) [8–10].
However, these reports pertain to the strains isolated from clinical
cases of deep-seated mycosis, and few studies have been pub-
lished concerning oral candidiasis (OC). Consequently, insufﬁcient
data of Candida strains in Japanese OC patients are available to
assess the differences in susceptibility, resistance, and changes with
time, compared with non-Japanese OC strains. Moreover, when
treating OC, it is necessary to evaluate the susceptibility of the
Candida strains timely isolated from clinical cases of OC to anti-
fungal drugs. The present study was undertaken to evaluate the
anti-fungal activity of AMPH-B, ﬂucytosine (5-FC), FLCZ, micona-
zole (MCZ), itraconazole (ITCZ), and micafungin (MCFG) against
Candida strains isolated from the oral cavity of OC patients who
visited Kagoshima University Hospital, and to access the isolation
frequency of resistant Candida strains in comparison with interna-
tional and other Japanese studies. The effectiveness of treatment
evier Ltd. All rights reserved.
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ith AMPH-B syrup, MCZ  gel, and ITCZ solution in OC patients
as also evaluated in order to provide information useful for the
reatment of OC.
.  Subjects and methods
.1.  Subjects
The study covered 116 strains isolated from clinical cases with
roblems of the oral mucosa, i.e. patients having been screened
or Candida at the Department of Oral Surgery, Kagoshima Univer-
ity Hospital, during the 24-month period from January 2006 to
ecember 2007. The strains collected from patients having received
nti-fungal drug therapy within 3 months prior to screening were
xcluded from this study.
.2.  Analysis of background variables of patients in whom
andida was isolated
Among  the 106 patients from whom Candida was  isolated,
nalysis was conducted for age, sex, underlying systemic disease,
resence/absence of steroid hormone treatment, denture use, chief
omplaints, and oral disease. In cases in which anti-fungal drugs
AMPH-B, MCZ, and ITCZ) had been used after diagnosis of OC, their
fﬁcacies were also investigated.
.3.  Collection and culture of Candida from the oral cavity
Prior  to the diagnosis of OC and the treatment with anti-fungal
rugs, the affected area of the oral cavity was wiped with a sterile
otton swab pre-immersed in sterile physiological saline solution,
nd the ﬂuid collected in this way was smeared onto a CHROMagar
andida Culture Medium (Nippon Becton and Dickinson Company,
td., Tokyo, Japan), followed by 48-h incubation at 36 ◦C.
.4.  Method for identiﬁcation of Candida species
Candida species were identiﬁed by the color of colonies formed
nd were conﬁrmed using the polymerase chain reaction method
eported by Kanbe et al. [11].
.5. Method for diagnosis of OC
The ﬂuid collected with a swab from the affected area was
pplied onto a glass slide for Gram staining using routine methods.
 diagnosis of OC was made in cases in which colony formation was
oted during incubation and the presence of pseudomycelium was
hown by Gram staining [12].
.6. Method for evaluation of susceptibility to anti-fungal drugs
The  Candida strains detected in the above-mentioned steps were
pplied again onto Sabouraud agar medium (Nippon Becton and
ickinson), followed by 48-hour incubation at 36 ◦C. The minimum
nhibitory concentration (MIC) values of AMPH-B, 5-FC, FLCZ, MCZ,
TCZ, and MCFG against these Candida strains were determined
ith a Yeast-like Fungal Sensitivity Kit ASTY (Kyokuto Pharma-
eutical, Tokyo Japan) compatible with the US National Committee
or Clinical Laboratory Standards (NCCLS) M-27A method [13]. The
trains with high MIC  values were subjected to re-measurement of
IC  with a Yeast-like Fungal DP Eiken kit (Eiken Chemical, Tokyo,
apan) compatible with the Clinical and Laboratory Standards Insti-
ute (CLSI) M27-A3 method [14].ternational 10 (2013) 87– 94
2.7.  Method for evaluation of the efﬁcacy of anti-fungal drug
therapy
The  responses to anti-fungal drug therapy were evaluated after
14 days of treatment. The following cases were rated as responders:
(1) cases with alleviated chief complaints; (2) cases free of Candida
in the culture; and (3) cases free of pseudomycelium in a Gram-
stained swab sample from the affected area. AMPH-B and MCZ
were administered to patients with OC other than hypertrophic OC,
because these drugs were hardly absorbed in the gastrointestinal
tract and are not usually prescribed for patients with hypertrophic
OC: AMPH-B (Fungizone Syrup, 100 mg/mL) was given 4 times a
day at 1 mL  for 12 days; MCZ  (Florid Oral Gel 2%, Mochida Pharma-
ceuticals, Tokyo, Japan) was  given at 10–20 g per day divided into
2–4 doses for 14 days; and ITCZ (Itrizole Oral Solution 1%, Janssen
Pharma, Beerse, Belgium) was  given at 20 mL  a day before food.
3. Results
3.1. Background variables
The  main symptoms among the 106 patients in whom Can-
dida was  detected were oral heat sensation (64 cases), pain of the
oral cavity (27 cases), dysgeusia (19 cases), oral dryness (17 cases),
oral mucosa leukoderma (leukoplakia) (10 cases), and oral mucosal
redness/erosion (10 cases). Heat sensation was  the most common
symptom in both OC (46.5%) and non-OC patients (47.4%). Oral dry-
ness in OC patients (44.4%) and leukoderma in non-OC patients
(21.0%) were also frequently observed. Underlying systemic dis-
eases included endocrine diseases in 28 cases (diabetes mellitus
14 cases, hypothyroidism 14 cases), cardiovascular disease in 21
cases, gastrointestinal disease in 16 cases, malignant tumor (other
than oral tumor) in 10 cases, neuropsychiatric disease in 8 cases
(depression in 6 cases), viral disease in 8 cases (viral hepatitis in 4
cases, human immunodeﬁciency virus infection in 3 cases, adult
T-cell leukemia in 1 case), and autoimmune disease in 6 cases.
Twenty-three patients were free of underlying systemic disease.
Steroid hormones had been used in 12 cases (systemic treatment in
6 cases, topical treatment in 6 cases). Most systemic diseases were
endocrine disease among OC patients (28.8%) and gastrointestinal
disease among non-OC patients (20.4%). One-ﬁfth of patients in
both groups had no systemic disease. Fifty-seven of the patients
had dentures.
Among 106 subjects in the present study, oral diseases included
OC in 57 cases (pseudomembranous oral candidiasis in 42 cases,
erythematous oral candidiasis in 11 cases, mixed pseudomembra-
nous/erythematous oral candidiasis in 2 cases, and hypertrophic
oral candidiasis in 2 cases) (Table 1) and non-OC in 49 cases (oral
lichen planus in 34 cases, glossalgia in 22 cases, Sjögren’s syndrome
in 17 cases, oral malignant tumor in 14 cases, oral leukoplakia in
13 cases, oral mucositis in 3 cases).
Candida was isolated from 30 males and 76 females. The age
of these patients ranged from 26 to 90 years (mean: 72.5 years)
(Table 1). There were no signiﬁcant differences in the number of
patients, male-to-female ratio, or age between the OC group and
the non-OC group (Table 1).
3.2. Isolated Candida species
In  total, 116 strains of Candida were isolated from patients in this
study. The most frequently isolated Candida species was  C. albicans
(93 strains), followed by C. glabrata (19 strains) and C. tropicalis (4
strains) (Table 2). There was  no signiﬁcant difference in the number
of Candida strains between the OC and the non-OC groups (Table 2).
However, C. albicans was  detected in almost all OC patients (56
Y. Kamikawa et al. / Oral Science International 10 (2013) 87– 94 89
Table  1
Background variables of OC patients and non-OC patients in the study.
Variables OC patients (%) Non-OC patients (%)
No. of study patients 57 49
Gender
Male 19 (33.3) 11 (22.5)
Female 38 (66.7) 38 (77.6)
Age
Mean ± SD 67.9 ± 15.4 69.3 ± 12.1
[Minimum –
Maximum]
[26–90] [34–89]
Median 71 73
[25th percentile –
75th  percentile]
[61–80] [63–76]
Pseudomembrane-
ous
candidiasis
Clinical type of candidiasis
Erythematous
candidiasis
42 (73.7)
Mixed
pseudomembrane-
ous/erythematous
candidiasis
11 (19.3)
Hypertrophic 2 (3.5)
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Table 3
Effects of prescription of the anti-fungal drugs AMPH-B, MCZ, and ITCZ in patients
with  various types of OC.
AMPH-B MCZ ITCZ
Number pf patients prescribed with
anti-fungal drug
28  27 2
Type of OC
Pseudomembraneous OC 19 17 0
Erythematous OC 8 9 0
Mixed
pseudomemraneous/erythematous
OC
1 1 0
Hypertrophic OC 0 0 2
Result of prescription
Chief  complaint alleviated 27 26 2
Culture negative 22 24 2candidiasis
C, oral candidiasis; SD, standard deviation.
trains in 57 OC patients, 98.2%), and in signiﬁcantly fewer non-OC
atients (37 strains in 49 non-OC patients, 75.5%).
.3. Treatment of OC and its effects
Anti-fungal drugs were prescribed for 57 patients diagnosed
ith OC, and no drug was prescribed for the 49 non-OC patients. The
nti-fungal drugs prescribed were AMPH-B in 28 cases, MCZ  in 27
ases, and ITCZ in 2 cases. In evaluation of responses to treatment
ith these drugs, the main symptom was alleviated in 55 cases.
n the remaining 2 cases, although the main symptom (oral heat
ensation) was not alleviated, Candida was not detected in the cul-
ure and no pseudomycelium was found in the Gram-stained swab
pecimens. After 14 days of treatment with anti-fungal drugs in the
7 patients, no Candida was detected in the culture in 48 patients,
ut C. albicans was still detected in 9 patients in whom no pseu-
omycelium was observed. It was thus judged that treatment was
ffective in all 57 cases and no apparent difference in effectiveness
as noted among the anti-fungal drugs used in the study (Table 3).
.4. Susceptibility to drugs
.4.1.  AMPH-B
The  MIC  was found to be low (below 2 g/mL) in 114 (97.3%) of
he 116 strains, with high MIC  values (over 16 g/mL) recorded in
nly 2 strains of C. albicans isolated from OC patients. Susceptibili-
ies against AMPH-B of Candida species isolated from patients with
nd without OC were almost the same, but with low MIC50 val-
es ranging from 0.25 g/mL to 0.5 g/mL and low MIC90 values
anging from 0.25 g/mL to 2.0 g/mL (Table 4a).
able 2
umber of Candida strains isolated from OC patients and non-OC patients.
All patients OC patients Non-OC patients
Number of patients 106 57 49
Number of strains
C.  albicans 93 56 37
C. glabrata 19 8 11
C. tropicalis 4 1 3
Total 116 65 51
C, oral candidiasis.Pseudomycelium negative 28 27 2
AMPH-B, amphotericin B; MCZ, miconazole; ITCZ, itraconazole; OC, oral candidiasis.
3.4.2. 5-FC
The  MIC  was below 16 g/mL (the cut-off point set by CLSI M27-
S3) in 113 (97.5%) of the 116 strains, and 3 strains (2.5%) of C.
albicans showed high MIC  values (over 64 g/mL). MIC50 of 5-FC
against Candida species isolated in patients with and without OC
ranged from <0.125 to 0.25 g/mL, and MIC90 ranged from 0.125 to
16.0 g/mL in OC patients and from <0.125 to 2 g/mL in non-OC
patients; all these values were below the cut-off point (Table 4b).
3.4.3.  FLCZ
The  MIC  was  below 32 g/mL (the cut-off point set by CLSI
M27-S3) in 105 (90.5%) of the 116 strains. High MIC values (over
64 g/mL) were recorded in 11 strains (9.5%), i.e. 4 strains of C.
albicans, 3 strains of C. glabrata, and 4 strains of C. tropicalis which
were all rated as FLCZ-resistant strains. Non-albicans species of
Candida (7 strains) were predominant among the FLCZ-resistant
strains, and no apparent difference in the number of FLCZ-resistant
strains was  observed between OC (5 strains, 7.7%) and non-OC
patients (6 strains, 11.8%). In OC patients MIC50 was  0.5 g/mL and
MIC90 was  4.0 g/mL against C. albicans, and 4.0 g/mL (below the
cut-off point) and >64 g/mL (above the cut-off point) against C.
glabrata, respectively. Both MIC50 and MIC90 against C. tropicalis
were >64.0 g/mL (above the cut-off point) (Table 4c).
3.4.4. MCZ
The  MIC  in 107 (92.2%) of the 116 strains was below 2 g/mL.
High MIC  values (over 4 g/mL) were recorded in 9 strains (7.8%),
consisting of 3 strains of C. albicans, 4 strains of C. glabrata, and
2 strains of C. tropicalis. Thus, non-albicans species of Candida (6
strains) were predominant among the Candida strains with high
MIC values for this drug. Isolation frequency of strains with high
MIC values was almost the same in OC (5 strains, 7.7%) and non-
OC patients (4 strains, 7.8%). In patients with OC  or non-OC, both
MIC50 (0.125 g/mL) and MIC90 (0.25 g/mL) against C. albicans
were low. Whereas MIC50 against C. glabrata was  low (1.0 g/mL),
MIC90 against this species was high (4.0 g/mL) in both OC and
non-OC patients. In non-OC patients both MIC50 (4.0 g/mL) and
MIC90 (over 16 g/mL) were high against C. tropicalis (Table 4d).
3.4.5. ITCZ
The  MIC  in 91 (78.5%) of the 116 strains was less than 1 g/mL
(the cut-off point set by CLSI M27-S3). High MIC values (over
1 g/mL) were recorded against 25 strains (21.6%), consisting of 9
strains of C. albicans, 12 strains of C. glabrata, and 4 strains of C. trop-
icalis, all of which were rated as ITCZ-resistant strains. Non-albicans
species of Candida (18 strains) were predominant among the ITCZ-
resistant strains, and the isolation frequency of resistant strain in
non-OC patients (14 strains, 27.5%) tended to be higher than that in
90
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Table 4a
Susceptibility of Candida strains isolated frrom OC patients and non-OC patients against amphohtericin B.
Amphotericin B (AMPH-B)
OC/Non-OC Strain Number of MIC  (g/mL) MIC50 MIC90
strains <0.03 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 >16
OC C. albicans 56 8 43 3 2
(14.3)  (76.8) (5.4) (3.6) 0.5 0.5
C.  glabrata 8 1 2 2 2 1
(12.5)  (25.0) (25.0) (25.0) (12.5) 0.5 2
C.  tropicalis 1 1
(100) 0.25 0.25
Non-OC C.  albicans 37 6 28 3
(16.2) (75.7) (8.1) 0.5 0.5
C.  glabrata 11 3 6 2
(27.3) (54.5) (18.2) 0.5 1
C.  tropicalis 3 2 1
(66.7)  (33.3) 0.5 1
OC, oral candidiasis; MIC, minimum inhibitory concentration Parentheses: % total number of strains.
Table  4b
Susceptibility of Candida strains isolated frrom OC patients and non-OC patients against ﬂucytosine.
ﬂucytosine (5-FC)
OC/Non-OC Strain Number of MIC (g/mL) MIC50 MIC90
strains <0.125 0.125 0.25 0.5 1 2 4 8 16 32 64 >64
OC C. albicans 56 18 8 24 3 1 2
(32.1)  (14.3) (42.9) (5.4) (1.8) (3.6) 0.25 0.5
C.  glabrata 8 4 1 1 2
(50.0) (12.5) (12.5) (25.0) <0.125 16
C.  tropicalis 1 1
(100) 0.125 0.125
Non-OC C.  albicans 37 23 2 9 1 1 1
(62.2)  (5.4) (24.3) (2.7) (2.7) (2.7) <0.125 0.25
C.  glabrata 11 10 1
(90.9) (9.1) <0.125 <0.125
C.  tropicalis 3 1 1 1
(33.3) (33.3) (33.3) 0.25 2
OC, oral candidiasis; MIC, minimum inhibitory concentration Parentheses: % total number of strains Broken line: breakpoint (CLSI M27-S3).
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Table 4c
Susceptibility of Candida strains isolated frrom OC patients and non-OC patients against ﬂuconazole.
ﬂuconazole (FLCZ)
OC/Non-OC Strain Number of MIC (g/mL) MIC50 MIC90
strains <0.125 0.125 0.25 0.5 1 2 4 8 16 32 64 >64
OC C. albicans 56 22 22 5 1 1 1 1 3
(39.3)  (39.3) (8.9) (1.8) (1.8) (1.8) (1.8) (5.4) 0.5 4
C.  glabrata 8 1 2 2 1 1 1
(12.5)  (25.0) (25.0) (12.5) (12.5) (12.5) 2 >64
C.  tropicalis 1 1
(100) >64 >64
Non-OC C.  albicans 37 1 13 12 4 1 2 2 1 1
(2.7)  (35.1) (32.4) (10.8) (2.7) (5.4) (5.4) (2.7) (2.7) 0.5 8
C.  glabrata 11 1 2 2 2 2 2
(9.1)  (18.2) (18.2) (18.2) (18.2) (18.2) 4 >64
C.  tropicalis 3 3
(100) >64 >64
OC, oral candidiasis; MIC, minimum inhibitory concentration Parentheses: % total number of strains Broken line: breakpoint (CLSI M27-S3).
Table  4d
Susceptibility of Candida strains isolated frrom OC patients and non-OC patients against miconazole.
miconazole (MCZ)
OC/Non-OC Strain Number of MIC (g/mL) MIC50 MIC90
strains <0.03 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 >16
OC C.  albicans 56 2 22 20 8 1 3
(3.6)  (39.3) (35.7) (14.3) (1.8) (5.4) 0.125 0.25
C.  glabrata 8  1 2 2 1 2 1 4
(12.5)  (25.0) (25.0) (12.5) (25.0)
C.  tropicalis 1  1
(100) 0.125 0.125
Non-OC C.  albicans 37  1 1 10 11 11 2 1
(2.7) (2.7) (27.0) (29.7) (29.7) (5.4) (2.7) 0.125 0.25
C.  glabrata 11 2 2 4 1 2
(18.2)  (18.2) (36.4) (9.1) (18.2) 1 4
C.  tropicalis 3 1 1 1
(33.3)  (33.3) (33.3) 4 >16
OC, oral candidiasis; MIC, minimum inhibitory concentration Parentheses: % total number of strains.
9 nce International 10 (2013) 87– 94
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C patients (11 strains, 27.5%). MIC50 and MIC90 against C. albicans
ere 0.06 g/mL and 1.0 g/mL in OC patients and 0.06 g/mL
nd 0.5 g/mL in non-OC patients, respectively. In OC and non-OC
atients, MIC50 and MIC90 against C. glabrata and C. tropicalis were
igh (>8 g/mL), with the exception of MIC50 against C. glabrata in
C patients (Table 4e).
.4.6.  MCFG
The  MIC  in 114 (98.2%) of the 116 strains was below 2 g/mL.
igh MIC  values (over 16 g/mL) were recorded in only 2 strains
7.8%) in OC patients, i.e. 1 strain of C. albicans and 1 strain
f C. glabrata, which were considered as refractory strains. In
C patients, both MIC50 (<0.03 g/mL) and MIC90 (0.06 g/mL)
gainst C. albicans were low. Similar susceptibility was  observed
n non-OC patients. In OC patients, MIC50 against C. glabrata
as low (0.125 g/mL) but MIC90 against this species was high
over 16 g/mL), while values in non-OC patients were 0.25 g/mL
nd 0.25 g/mL, respectively. Both MIC50 (0.06 g/mL) and MIC90
0.06–0.125 g/mL) against C. tropicalis were low in OC and non-OC
atients (Table 4f).
.  Discussion
In many cases, candidiasis, including OC, is an endogenous
pportunistic infection that manifests only after abnormalities
n local or systemic protective mechanisms. Candida is a normal
nhabitant with few symptoms in healthy individuals. However,
C infection can easily develop in patients with underlying dis-
ase (including blood dyscrasia, immunodeﬁciency diseases, and
iabetes), and in those with dysfunctional systemic protective
echanisms due to immunosuppressant medication or treatment
ith an antimicrobial drug, and thus changes in the local envi-
onment of the mouth. Infants and elderly people with reduced
esistance are also vulnerable.
.1.  Isolation frequency and MICs
In the present study, 116 Candida strains were obtained from
06 patients who  suffered from oral discomfort: 57 OC patients
nd 49 non-OC patients. OC was deﬁned as the presence of colony
ormation during incubation and of pseudomycelium as shown by
ram staining [12]. OC and non-OC are sometimes confused in
 clinical setting, because Candida strains are similarly detected
nd the main symptoms and underlying systemic diseases are
lmost the same in both OC and non-OC patients despite some dif-
erence in isolation frequency as observed in the present study.
ore precisely, 56 strains of C. albicans were isolated in 57 OC
atients (98.2%), which is signiﬁcantly higher than those isolated
n non-OC patients (37 C. albicans strains in 49 non-OC patients,
5.5%), indicating C. albicans was a dominant causal fungal species
n OC.
In  Japan, very few reports are available on the effects of anti-
ungal drugs against Candida strains isolated from the oral cavity of
C patients, and most of the studies used Candida strains obtained
rom deep-seated candidiasis or oral diseases including OC to deter-
ine their susceptibility against anti-fungal drugs. The present
tudy enrolled both OC and non-OC patients. Although 5-FC and
CFG showed high MIC90 values against C. glabrata (a non-albicans
pecies), especially in OC patients, there were no obvious differ-
nces in terms of anti-fungal MIC  values between OC and non-OC
atients. Moreover, susceptibility to Candida strains in the present
tudy was not different from that reported in previous studies. In
apan, Sudo et al. evaluated the in vitro susceptibilities to antifungal
gents of 74 clinical isolates of Candida from AIDS patients with OC
r esophageal candidiasis, and the MIC90 values against C. albicans, a
epresentative Candida in OC, were almost the same except for FLCZ Ta
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(16 and 4 g/mL in Sudo et al. and our studies, respectively) [14,15].
Regarding isolation frequency, C. glabrata was hardly detected by
Sudo et al., but was detected at 12.3% in our study. The surveillances
conducted in 2001 and later, as discussed below, demonstrated
higher isolation frequency of C. glabrata by more than 20%, indi-
cating that there must be changes in isolation frequency of Candida
strains by year [7–10]. Compared with the isolation frequency of
Candida strains in international studies by Blignaut et al. in 2002
[16], Kuriyama et al. in 2005 [17], and Hamza et al. in 2008 [18],
in which oral isolates in OC patients were also tested, C. albicans
was dominant but C. glabrata was  increased in our study (12.3% and
1.6–9.5% in our study and other studies, respectively), whereas MIC
values were similar. Thus, although susceptibility to Candida strains
in OC patients in the present study was not signiﬁcantly different
from that of other studies within and outside Japan, geographic and
temporal alteration of the isolation frequency was observed.
4.2.  Resistant strains
Regarding  resistant Candida strains, Japan Invasive Mycosis
Surveillance (JIMS) [7] and 99 Japan Antifungal Surveillance (JAS)
[8–10] were conducted mainly among patients with deep myco-
sis as nationwide surveillance. Although resistant C. albicans was
hardly found in either surveillance study, there was  a small dif-
ference in incidence of resistant non-albicans, attributable to the
detection procedure of resistant fungi. Namely, there was a big dif-
ference in resistance frequency depending on incubation time (24
or 48 h) in JIMS [7] and methods employed (JSMM and M27-A2
methods) in JAS [8]. In the present study conducted based on the
M27-A2 method, all anti-fungal drugs except ITCZ demonstrated
a low frequency of C. albicans resistance below 5%. In the case of
ITCZ, the frequency of resistant C. albicans was  10.7% and 8.1% in
OC and non-OC patients, respectively, being modestly higher than
for other drugs. The frequency of resistant C. glabrata against ITCZ
was most remarkable at 50.0% and 72.7% in OC and non-OC patients,
respectively. One possible explanation for this ﬁnding is that ITCZ
is a compound with relatively low solubility in water and is likely
to precipitate at high concentrations, resulting in a lower effective
concentration as compared with its nominal concentration. This
phenomenon can be seen not only with a homemade plate for sensi-
tivity measurement but also with commercial kits, suggesting that
its cause is associated with the method for preparing the reagent
[19].
As mentioned above, since isolation frequency of C. glabrata in
OC patients is increasing, it is important for the treatment of OC
to precisely assess changes in isolation frequency of C. glabrata
as well as C. albicans resistant strains. In the present study, C.
glabrata resistant strains were found against MCZ  at a frequency
of 25%, FLCZ at 12.5%, and ITCZ at 50%; these values are higher
than for other Candida resistant strains. Thus C. glabrata resis-
tant strains would increase in parallel with an increase in C.
glabrata.
4.3. Effects of anti-fungal treatment
In the present study, MCZ  and ITCZ were used in some of
the cases in which Candida strains with high MICs of azole anti-
fungal drugs were isolated, but treatment with these drugs was
effective in these cases (Table 3). When interpreting this result,
although we  cannot rule out the possibility that there was  a prob-
lem with the method employed for susceptibility assessment [19],
it seems more likely that the result reﬂects double actions of ITCZ
(Itrizole Oral Solution), i.e. a direct but transient action in the
oral cavity and action in the blood after absorption enhanced by
improving intestinal absorption of an oral dose [20]. Thus for refrac-
tory OC, such as hypertrophic OC, ICTZ solution is effective with
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ocal and systemic anti-fungal effects [21]. Since MCZ  and AMPH-
 are hardly absorbed from the gastrointestinal tract or are easily
etabolized by the ﬁrst-pass effect in the liver, their anti-fungal
fﬁcacies are attributable to local but not systemic effects. There-
ore, MCZ  and AMPH-B are preferably prescribed to OC patients
ith pseudomembranous and erythematous OC. In the case of MCZ
dministered in the form of gel, it remains for a relatively long
uration in the oral cavity at a much higher concentration than the
IC  [22], exerting direct and potent inhibitory action against oral
andida species even in OC patients with Candida strains with resis-
ance or a tendency toward resistance against anti-fungal drugs.
his indicates the importance of a high local concentration of the
ctive pharmaceutical ingredients over high MIC  values in the oral
avity is requisite for exerting their efﬁcacy against OC. Devel-
pment of a new topical anti-fungal drug enabling a sustained,
igh local concentration with lower frequency of administration
s expected.
. Conclusions
Susceptibility and resistance of Candida strains isolated from OC
atients against 6 anti-fungal drugs (AMPH-B, 5-FC, FLCZ, MCZ,
TCZ, and MCFG) were evaluated and found to be not different
rom those obtained from non-OC patients. Three anti-fungal drugs,
MPH-B, MCZ, and ITCZ, given to OC patients were found to be
ffective against OC in spite of differences in MIC  values and in the
umber of resistant strains (or strains with a high MIC  value). In
he case of local treatment with anti-fungal drugs, a high local con-
entration and prolonged retention of the drug in the oral cavity
re crucial for potent efﬁcacy against OC.
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